On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
While lilkahuna is humble and self-effacing, he is never wrong about IPIX and diction (except when he is).
It’s still not a “conflation.” It’s a subject change. Though, it does explain the “Brilacidin” “typo.” Please note 1) typo is in quotes and 2) I’m not apologizing.
Not “conflating” in any sense of the word. It was an obvious typo as petemanx had already stated Prurisol before typing Brilacidin and in the very next sentence he typed Prurisol, again.
And, he is right. The more severe the cases are, the less placebo effect, and there should be increased separation between drug and placebo.
“In October, the final patient in a Phase 2 trial of Brilacidin for OM in cancer patients completed treatment. This was a randomized, placebo-controlled clinical trial of Brilacidin-OM (see NCT02324335) in 61 patients. According to CEO Leo Ehrlich, that study will be un-blinded and top-line data will be released in about a week.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136587267
The PR confirmed the end of dosing (an important benchmark), and the last follow up and final data collection are less than 4 weeks away (another benchmark) It also confirmed the trial is still on schedule for completion and close before 2018 (a milestone), something many were claiming would be delayed until almost mid-2018. Top line data will soon follow; as some mentioned maybe in time for the big SF presentation in January.
It was an important update to many of us. And I’m glad the market responded slowly and the SP dipped before taking off.
My guess is the BP that advised for OM is the same one for UP and ABSSSI. The evidence I see points to a BP that wants the B platform and has the resources to develop all potentials. So, in that sense you are right that OM increases the value of ABSSSI.
Looks like some wanted to take it down before stepping in with buying. Should close green with more tomorrow. I wonder if any of that was rabbit induced tax loss selling? Lol.
I agree with your more likely 300 to 500 percent run as opposed to any further decline.
I want to thank everyone who helped me pick up a few thousand more .69s this morning. Thank you. Thank you so much.
Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2b Study of Oral Prurisol for Psoriasis
Prurisol November 30, 2017
BEVERLY, Mass., November 30, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has completed study treatment in the Company’s Phase 2b trial of Prurisol for the treatment of psoriasis. Prurisol is being developed as a novel, nonbiologic, oral psoriasis drug candidate.
A total of 199 patients were enrolled in the clinical trial (see NCT02949388), which includes: a screening period of up to 4 weeks; a treatment period of 12 weeks; and a follow-up visit at 4 weeks, post-treatment. The randomized, double-blind, parallel-group and placebo-controlled study increased the total daily oral dosing of Prurisol from a previous high of 200 mg to include oral Prurisol 300 mg per day, oral Prurisol 400 mg per day, and placebo (3:1:3 randomization). Primary efficacy is being evaluated using the Psoriasis Area and Severity Index (PASI), enabling a more direct comparison to already approved psoriasis drugs. In addition, multiple secondary endpoints will be studied to provide further insights into the potential benefits of Prurisol compared to marketed therapies, both oral and biologic.
In a previous Phase 2 trial studying Prurisol in mild-to-moderate psoriasis (see NCT02494479), Prurisol demonstrated early efficacy and was shown to be well-tolerated. A summary of these Phase 2 study results, presented at the 14th Annual Discovery on Target Conference, which was held on September 19, 2016, can be accessed at the link below.
· “Prurisol: A New Small Molecule Under Investigation for the Treatment of Psoriasis”
http://www.ipharminc.com/s/Prurisol-Presentation-for-Med-Derm-RD-Workshop_19Sep2016-u.pdf
“With all patients having received treatment, we look forward to wrapping up the Phase 2b Prurisol trial,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Only a handful of patient follow-up visits remain to be completed. A novel psoriasis drug, particularly one that is oral, safe and effective, would be well-received by clinical practitioners and patients alike, both looking for newer treatment options to help manage this debilitating skin disease
That’s because there have been multiple data sets coming is consistently since 2015. B-OM is a game changer as it is an unmet need. If the final data is just similar to the interim, there will be a deal in 2018. Leo has already said as much.
Picked up more lPIX last week and will likely buy more on a Wednesday/Thursday dip. Looking good here as we approach December.
And, thanks MTGDVL! Ten years in the making of Lilkahuna, and I don’t mean my trading account. Ha!
It’s the smart thing to do. Keep a superior drug off the market, if P delivers superiority, and extend market dominance beyond Oezla.
Yes, corporations only make decisions based on one year costs and projected revenue. Yes, they have long-term plans, but look mostly at short-term profits. Tying up >$5 billion for more then 5 years with no return on investment is unlikely if for no other reason than the CEO is unlikely to be there 5 years out.
I was saying nothing more than why they might want Prurisol. Yes, unlikely, but they could retain their market by first stalling P advancement, then shifting existing clients to Prurisol as Otezla turns generic. It’s the smart thing to do, but corporations tend to look only a year out, not ten years.
Otezla’s patent and market protection expire in about 5 years, if I recall correctly. Prurisol patents expire about 10 years after plus whatever market protection beyond that (at least 3 more years). Celgene could easily drag its feet advancing prurisol until just before all protection expires. They would then continue to have a market exclusive drug continuously for at least another 12 years. I don’t see Leo and Krishna going to Celgene unless a buyout of Prurisol for hefty billions.
You are correct.
He spent millions on designing and preparing the Phase 3 trial? That is complete bullshit. No way to sugar coat it.
Oh, bullshit. When the Brilacidin asset was acquired, ABSSSI was the low hanging fruit, and the end of Phase 2b assessment and design proposal for Phase 3 wasn’t at all expensive. In the meantime UP and OM emerged from preclinical testing and ready for Phase 2a. Also, the FDA decided they wanted twice as many subjects as that in the ABSSSI proposal, which made the trial far more expensive than Leo had both thought and hoped. Leo could not have known what you suggest until he heard from the FDA. He must have already had the Plan B ready—go with UP and OM—before the FDA feedback considering how quickly the trials started after setting aside ABSSSI.
As explained so many times, ABSSSI is waiting for fuller valuation of the entire B platform by demonstrating conclusively it’s anti-inflammatory and other properties. That fuller valuation will come after OM and UP results. And, UP and OM are both in areas of unmet need as opposed to ABSSSI which is already competitive. Not acknowledging this doesn’t make it any less true. It’s as though some BP wants to know this before licensing or partnering the platform.
A major PR on a day with a 99 share volume in the first 15 minutes of trading? As a realist (rather than posts rated as pro) I know what short trading days are all about. A PR today will get crushed come Monday.
Thanksgiving thoughts from across the grand ocean:
Give thanks for those around you at your Thanksgiving feast, no matter whose company you are in or where you may be.
Give thanks and cherish loved ones, both family and friends.
Give thanks for those no longer with you whose past presence helped influence you to become who you are today.
Give thanks to all those you have encountered in your life for each has left you something whether a passing smile or a learning moment out of tens of thousands.
Give thanks to those strangers who have gifted you, blessed you, with the many comforts of society, culture and technology. All those visionaries from whom we received all the comforts, freedoms and guaranteed rights from the earliest authors of writs to the programmers and designers responsible for the very technology upon which you are reading this.
Give thanks to those many strangers and possibly current family and ancestors from whose sacrifices we enjoy all these freedoms. Remember, not all who paid the ultimate price were soldiers, yet for the lost soldier there is a special thanks.
Today I give thanks for all my blessings though I am in an emerging nation that now allows teachers like me to pass on my knowledge and share with its citizen children some of my lifelong learning and lessons. For this last thing, and as an old man in his autumn of life, I am especially thankful.
Happy Thanksgiving and prosperity to all be it the blessing of wealth,
abundant love, or future generations. God bless us all. --LilKahuna
OM results are late? How do you figure? Last I recall, OM results were updated months ago as expected in q4 2017. I believe we are still in q4, yes?
In this case I prefer “the cur is worse than the disease.”
Parked on the .7 bid all day isn’t “gobbling them up”. It’s stealth buying. I know because I was parked on .7 bid all day just waiting for MMs to walk it to me, feed me. I felt like one of those angler fish. “Look at this tender morsel. A little closer. A little closer. A little closer. Gotcha!
Or how about:
Brilacidin is ineffective (conflating data)
The company is hiding data for P
K is a scam because if Abacavir was effective it would already be in use for p53
Cellceutix is a shell company
All the above were stated by Mako in its hit piece. So, where were the issues that were true that led to claims of short and distort?
bullshit
Another post of exaggeration and fantasy. Another post focused on non-events ignoring the reality of 5 (going on 6) successful trials without a single failure while achieving all outcomes.
Beginning to look like it. I really don’t need any more shares. But, it’s a long holiday trading week and another week before December news. FUD mongers might still get it down another 3 cents.
Again, your post fails to even acknowledge that every milestone in guidance over the past 5 years has come to pass. Everything that has been just around the corner actually has been around the corner once turned. Your post conflates past events into a single event. In other words, a lie.
What’s laughable is failure to acknowledge anything but exaggerated and imagined flaws. What’s laughable is the entire focus on past and present share price and not recognize for even a moment what’s coming in the next 30 days.
My stink bid is now .68. I’ll raise it a little if the holiday week turns strong, before it fills. ;-D
Sure wish posts would say things like “up to $80 a share depending on path to approval and terms of partnership.” If B-OM gets breakthrough designation. If it is aporoved within the year based on low systemic exposure of B in circulation. If it is rapidly adapted in oncology and then immunotherapy and other immune compromising treatments. If the milestones include graduated royalty structure increasing with sales. Then it could be worth up to $80 a share (maybe a little more).
Yes, all 3 platforms could be worth up to $400 a share based on similar conditions and contingencies. But...
Regarding the PR, I’ve passed easier gallstones when compared with today’s parsing of “to” vs “with.”
It clearly means IPIX will move B-OM forward to a pivotal trial regardless of whether or not a partnership or license is in place. It’s a reminder that the company has internal staff and resources to design, get approval and execute a Phase 3. Finally, in context of the rest of the PR, Leo is saying a partnership is best, but we don’t absolutely require one so BP pony up.
Very good PR to let us know OM data is unwinding and top line results are now pending. Seems to me those results could be as soon as next week, most probably by the end of this month. Also, if data is as good as interim, partnership in Q1 2018, if not by Christmas.
Maybe for approval it will take years, but monetizing can happen anytime after the current Phase 2 for OC. IPIX will need a partner for any pivotal cancer trial and said partner will pay a lot for rights and then milestones. I expect this to happen before 2019, but after B and then P.